(Total Views: 404)
Posted On: 04/05/2020 4:33:45 PM
Post# of 148899
Don’t even consider a buy out... We have the potential for as many as 4 FDA approvals this year and maybe more if you consider all 22 cancer indications as separate. Revenue is astronomical worldwide if that happens. Accepting an offer now before the revenue goes ballistic is just plain foolishness. We might be buying out Gilead or Merck down the road. We might be the biggest drug to ever hit the market. Why would anyone consider giving up that opportunity? You ran a few numbers but it doesn’t seem like you ran enough numbers to include the world market in those numbers.
If someone were to break down every indication for the USA and the rest of the world it is just as NP has stated. You must forget that he is a engineer and math is a strong subject for him. He has stated that this is not only a 3 digit stock in a couple of years but a high 3 digit stock or quite possibly 4 digit. I believe that he has stayed up late on sleepless night and worked the figures himself to know just what the potential is for this drug and it’s many indications. I hope to always be invested in this company and would never sell out for pennies on the dollar. You have to understand that the potential is beyond what anybody here on this board has worked out. It’s not that far from the biggest returns either.
NP stated not long ago that when MTNBC has FDA approval then How far is it to stretch that to all 22 other cancers since they have the same mechanism of action. Dr. Patterson will be instrumental in explaining the mechanism of action to the FDA. Nader is basically saying that they should be approved all together since it works the same for all indications. I agree with that statement. Even if he has to get approval on each separately which I can’t understand why the FDA would not approve. But even if they don’t the market is there to start prescribing for different cancers even if not approved. You just need one approval and the door opens to all of them for different indications. So don’t accept pennies on the dollar. Sell some stock here and there as the value goes astronomical and wait for the golden parachute at the end when you get to enjoy the fruits of your patience...
If someone were to break down every indication for the USA and the rest of the world it is just as NP has stated. You must forget that he is a engineer and math is a strong subject for him. He has stated that this is not only a 3 digit stock in a couple of years but a high 3 digit stock or quite possibly 4 digit. I believe that he has stayed up late on sleepless night and worked the figures himself to know just what the potential is for this drug and it’s many indications. I hope to always be invested in this company and would never sell out for pennies on the dollar. You have to understand that the potential is beyond what anybody here on this board has worked out. It’s not that far from the biggest returns either.
NP stated not long ago that when MTNBC has FDA approval then How far is it to stretch that to all 22 other cancers since they have the same mechanism of action. Dr. Patterson will be instrumental in explaining the mechanism of action to the FDA. Nader is basically saying that they should be approved all together since it works the same for all indications. I agree with that statement. Even if he has to get approval on each separately which I can’t understand why the FDA would not approve. But even if they don’t the market is there to start prescribing for different cancers even if not approved. You just need one approval and the door opens to all of them for different indications. So don’t accept pennies on the dollar. Sell some stock here and there as the value goes astronomical and wait for the golden parachute at the end when you get to enjoy the fruits of your patience...
(2)
(0)Scroll down for more posts ▼
